Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis

Boehringer Ingelheim716 enrolled

Overview

Study to obtain further information on the tolerability and efficacy of Ventilat® metered-dose inhaler in the treatment of Chronic Obstructive bronchitis under conditions of daily practice

Study Type

OBSERVATIONAL

Enrollment

716

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Ventilat® - metered dose inhalerDRUG

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primarily Patients of both genders older than 40 years, who suffer from Chronic Obstructive bronchitis * Only patients who have not been treated with an anticholinergic within the last year are to be considered for inclusion Exclusion Criteria: •Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Ventilat® metered dose inhaler

Outcomes

Primary Outcomes

Change in the clinical picture

Time frame: after 4 weeks

Secondary Outcomes

Assessment of efficacy by investigator on a 4-point scale

Time frame: after 4 weeks

Assessment of efficacy by patient on a 4-point scale

Time frame: after 4 weeks

Number of patients with adverse drug reactions

Time frame: up to 4 weeks

Assessment of tolerability by investigator on a 4-point scale

Time frame: after 4 weeks

Assessment of patient by investigator on a 4-point scale

Time frame: after 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.